The Advance of Biomarker-Driven Targeted Therapies in Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 May 2025 | Viewed by 60
Special Issue Editors
Interests: targeted therapy; cancer biology; biomarkers; tumor microenvironment; molecular biology
Special Issues, Collections and Topics in MDPI journals
Interests: target therapy; chemoprevention; tumor microenvironment; cancer biomarkers; childhood cancer
Special Issue Information
Dear Colleagues,
The rise of biomarker-driven targeted therapies marks a pivotal moment in cancer treatment, ushering in personalized approaches that leverage the distinct molecular traits of tumors. This Special Issue delves into the forefront of biomarker identification, validation, and application within the realm of targeted cancer therapies. Ranging from genomic alterations to protein expression patterns, the unraveling of biomarkers empowers clinicians to stratify patients, anticipate treatment responses, and refine therapeutic strategies more precisely. Additionally, this edition aims to spotlight the dynamic landscape of precision medicine, showcasing innovative technologies and computational tools instrumental in biomarker discovery and clinical translation. By presenting cutting-edge research and clinical perspectives, this Special Issue aims at deepening our comprehension of biomarker-guided targeted therapies and their profound impact on both the tumor microenvironment and immune therapy, ultimately advancing patient outcomes in cancer care.
Dr. Tianshun Zhang
Dr. Qiushi Wang
Dr. Ann Bode
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarkers
- targeted therapies
- precision medicine
- cancer treatment
- molecular profiling
- personalized medicine
- genomic alterations
- therapeutic interventions
- tumor microenvironment
- immune therapy
